It all comes to the results of the GMP, if it is a great success then it opens all doors for studies not cancer related..
Non dilutive funding was mentioned many times by the Dr, the sporadic event kept them at bay, if a successful GMP will they return? Dx3 does not need ph 1 trials for people to start their own research but confirmation of our product can be made at scale is a must
Ann: Presentation to highlight broader potential of Deoxymabs, page-46
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.46M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.8¢ | $8 | 1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 8034700 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1995944 | 7 |
View Market Depth
| Last trade - 10.06am 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.7¢ |
Change
0.000 ( 12.5 %) |
||||
| Open | High | Low | Volume | ||
| 0.7¢ | 0.7¢ | 0.7¢ | 30000 | ||
| Last updated 11.14am 27/05/2024 ? | |||||
| PAB (ASX) Chart |